KR970705578A - NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES) - Google Patents

NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES)

Info

Publication number
KR970705578A
KR970705578A KR1019970701103A KR19970701103A KR970705578A KR 970705578 A KR970705578 A KR 970705578A KR 1019970701103 A KR1019970701103 A KR 1019970701103A KR 19970701103 A KR19970701103 A KR 19970701103A KR 970705578 A KR970705578 A KR 970705578A
Authority
KR
South Korea
Prior art keywords
antibody
peptide
amino acid
acid sequence
seq
Prior art date
Application number
KR1019970701103A
Other languages
Korean (ko)
Inventor
반 두인 마르셀
얀 그루텐후이스 아리예
요한네스 분쇼텐 에베르트
Original Assignee
에프.지.엠. 헤르만스; 이.에이치. 리어링크
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프.지.엠. 헤르만스; 이.에이치. 리어링크, 악조 노벨 엔.브이. filed Critical 에프.지.엠. 헤르만스; 이.에이치. 리어링크
Publication of KR970705578A publication Critical patent/KR970705578A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 투명대 단백질 ZP3에 대한 면역 응답반응을 유도할 수 있는 펩티드에 관한 것으로, 상기 펩티드는 8-50개의 아미노산 잔기로된 아미노산 서열을 가지며, 최소한 아미노산 서열 PLWLLQ 또는 그 유사체를 포함한다. 더욱 구체적으로, 본 발명에 따른 펩티드는 최소한 아미노산 서열 QPLWLLQG를 포함한다. 본 발명의 또다른 구체예는 본 발명에 따른 펩티드에 대해 생성된 항체, 상기 펩티드 또는 항체를 함유하는 피임용 백신뿐아니라 시험 샘플중에서 ZP3에 대한 자가면역 항체를 검출하기 위한 시험 키트에 관한 것이다.The present invention relates to a peptide capable of inducing an immune response to ZP3, wherein said peptide has an amino acid sequence consisting of 8-50 amino acid residues and at least an amino acid sequence PLWLLQ or an analog thereof. More specifically, the peptides according to the invention comprise at least the amino acid sequence QPLWLLQG. Another embodiment of the present invention relates to a test kit for detecting an autoimmune antibody against ZP3 in a test sample, as well as a vaccine for pus containing the antibody, the peptide or the antibody produced against the peptide according to the present invention.

Description

신규의 면역피임 펩티드류(NEW IMMUNOCONTRACEPTIVE PEPTIDES)NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (19)

최소한 아미노산 서열 PLWLLQ(서열번호 1) 또는 ECACC에 수탁 번호 94032402로 기탁된 하이브리도마 세포주에 의해 생성된 모노클로날 항체들과 면역 반응성인 상기 아미노산 서열의 유사체를 포함하는, 8-50개의 아미노산 잔기로된 아미노산 서열을 가진 펩티드.And at least 8-50 amino acid residues comprising an amino acid sequence PLWLLQ (SEQ ID NO: 1) or an analog of said amino acid sequence that is immunoreactive with monoclonal antibodies produced by a hybridoma cell line deposited with Accession No. 94032402 to ECACC ≪ / RTI > 제1항에 있어서, 상기 펩티드가 최소한 아미노산 서열 QPLWLLQG(서열번호 2) 또는 그 유사체를 포함하는 것을 특징으로 하는 펩티드.2. The peptide of claim 1, wherein the peptide comprises at least the amino acid sequence QPLWLLQG (SEQ ID NO: 2) or an analog thereof. 제1항 또는 제2항에 있어서, 상기 펩티드가 아미노산 서열 QPLWLLQG(서열번호 2)를 갖는 것을 특징으로 하는 펩티드.3. The peptide according to claim 1 or 2, wherein the peptide has the amino acid sequence QPLWLLQG (SEQ ID NO: 2). 제1항 또는 제2항에 있어서, 상기 펩티드가 아미노산 서열 PQPLWLLQ(서열번호 5), PLWLLQGG(서열번호 6) 또는 LCYPQPLWLLQGGASHPETS(서열번호 7)을 갖는 것을 특징으로 하는 펩티드.3. The peptide according to claim 1 or 2, wherein the peptide has the amino acid sequence PQPLWLLQ (SEQ ID NO: 5), PLWLLQGG (SEQ ID NO: 6) or LCYPQPLWLLQGGASHPETS (SEQ ID NO: 7). 제1항 또는 제2항에 있어서, 상기 펩티드가 아미노산 서열 ADGAPMWTLQGAAGA(서열번호 8)를 갖는 것을 특징으로 하는 펩티드.3. The peptide according to claim 1 or 2, wherein the peptide has the amino acid sequence ADGAPMWTLQGAAGA (SEQ ID NO: 8). 제1항 내지 제5항 중 어느 한 항에 따른 펩티드를 항체 생성에 사용하는 방법.Use of a peptide according to any one of claims 1 to 5 for the production of an antibody. 제1항 내지 제5항 중 어느 한 항에 따른 펩티드에 대해 생성된 항체.An antibody produced against a peptide according to any one of claims 1 to 5. 제7항에 있어서, 상기 항체가 아미노산 서열 PLWLLQ 또는 QPLWLLQG를 포함하는 에피토프에 대한 특이적 결합능을 갖는 것을 특징으로 하는 항체.8. The antibody of claim 7, wherein said antibody has a specific binding potency to an epitope comprising the amino acid sequence PLWLLQ or QPLWLLQG. 제7항 또는 제8항에 있어서, 상기 항체가 모노클로날인 것을 특징으로 하는 항체.9. The antibody of claim 7 or 8, wherein the antibody is monoclonal. 제9항에 있어서, 상기 항체가 ECACC에 수탁 번호 94032402로 기탁된 하이브리도마 세포주에 의해 생성된 것임을 특징으로 하는 항체.10. An antibody according to claim 9, wherein the antibody is produced by a hybridoma cell line deposited with Accession No. 94032402 to ECACC. 제7항 내지 제10항 중 어느 한 항에 따른 항체를 생성하는 세포주.10. A cell line producing an antibody according to any one of claims 7 to 10. ECACC에 수탁 번호 94032402로 기탁된 하이브리도마 세포주.Hybridoma cell line deposited with Accession No. 94032402 to ECACC. 치료용 물질로서 사용하기 위한 제1항 내지 제5항 중 어느 한 항에 따른 펩티드 및/또는 제7항 내지 제10항 중 어느 한 항에 따른 1종 이상의 항체.A peptide according to any one of claims 1 to 5 for use as a therapeutic substance and / or one or more antibodies according to any one of claims 7 to 10. 제1항 내지 제5항 중 어느 한 항에 따른 1종 이상의 펩티드 또는 제7항 내지 제10항 중 어느 한 항에 따른 1종 이상의 항체 및 약학적 허용 담체를 함유하는 약학 조성물.10. A pharmaceutical composition comprising at least one peptide according to any one of claims 1 to 5 or at least one antibody according to any one of claims 7 to 10 and a pharmaceutically acceptable carrier. 제1항 내지 제5항 중 어느 한 항에 따른 1종 이상의 펩티드 또는 제7항 내지 제10항 중 어느 한 항에 따른 1종 이상의 항체 및 약학적 허용 담체를 함유하는 피임용 백신.10. A vaccine for pace containing one or more peptides according to any one of claims 1 to 5 or one or more antibodies according to any one of claims 7 to 10 and a pharmaceutically acceptable carrier. a) 환자로부터 혈청 샘플을 채취하는 단계, b) 상기 샘플을 제1항 내지 제5항 중 어느 한 항에 따른 1종 이상의 펩티드 및 선택적으로 본 발명에 따른 1종 이상의 항체를 함유하는 진단용 시약에 접촉시키는 단계, 및 c) 적절한 검출 반응에 의해 상기 자가면역 항체의 존재를 측정하는 단계를 포함하여, 환자의 혈청에서 자가면역 항체를 검출하는 방법.comprising the steps of: a) collecting a serum sample from a patient, b) contacting said sample with a diagnostic reagent comprising at least one peptide according to any one of claims 1 to 5 and optionally at least one antibody according to the invention And c) measuring the presence of said autoimmune antibody by an appropriate detection reaction. ≪ Desc / Clms Page number 20 > 진단용 물질로 사용하기 위한 제1항 내지 제5항 중 어느 한 항에 따른 펩티드 또는 제7항 내지 제10항 중 어느 한 항에 따른 항체.The antibody according to any one of claims 7 to 10 or a peptide according to any one of claims 1 to 5 for use as a diagnostic agent. 제1항 내지 제5항 중 어느 한 항에 따른 1종 이상의 펩티드 및 선택적으로 제7항 내지 제10항 중 어느 한 항에 따른 모노클로날 항체를 함유하는 진단용 시약을 포함하는, 시험 샘플중에서 자가면역 항체를 검출하기 위한 시험 키트.A test sample comprising at least one peptide according to any one of claims 1 to 5 and optionally a diagnostic reagent containing a monoclonal antibody according to any one of claims 7 to 10, A test kit for detecting an immune antibody. 검출제로 표지된, 제7항 내지 제10항 중 어느 한 항에 따른 모노클로날 항체를 함유하는 진단용 시약.A diagnostic reagent comprising a monoclonal antibody according to any one of claims 7 to 10, which is labeled with a detection agent. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701103A 1994-08-22 1995-08-18 NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES) KR970705578A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94202392 1994-08-22
EP94202392.0 1994-08-22
PCT/EP1995/003311 WO1996006113A1 (en) 1994-08-22 1995-08-18 New immunocontraceptive peptides

Publications (1)

Publication Number Publication Date
KR970705578A true KR970705578A (en) 1997-10-09

Family

ID=8217113

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701103A KR970705578A (en) 1994-08-22 1995-08-18 NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES)

Country Status (10)

Country Link
EP (1) EP0777688A1 (en)
JP (1) JPH10505340A (en)
KR (1) KR970705578A (en)
CN (1) CN1158623A (en)
AU (1) AU3471395A (en)
BR (1) BR9508748A (en)
CA (1) CA2198265A1 (en)
FI (1) FI970744A (en)
HU (1) HUT77262A (en)
WO (1) WO1996006113A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19622289A1 (en) * 1996-05-23 1997-11-27 Schering Ag Zona Pellucida Proteins for contraception
EP0923602A4 (en) * 1996-07-03 2005-06-15 Zygam Inc Immunocontraceptive compositions containing sperm antigens, and methods of use
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
BR9908096A (en) 1998-02-19 2000-10-31 Eastern Virginia Med School Recombinant, active, human skin zone protein (hzp3) 3
CA2456821A1 (en) 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
CN101906163B (en) * 2009-06-05 2012-06-27 上海交通大学医学院 Immunocontraceptive synthetic peptide and immunocontraceptive chimeric peptide and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996297A (en) * 1987-10-07 1991-02-26 Zonagen, Inc. Recombinantly expressed rabbit zona pellucida polypeptides
CA2058999A1 (en) * 1989-06-12 1990-12-13 Jurrien Dean Contraceptive vaccine based on cloned zona pellucida gene
WO1992003548A1 (en) * 1990-08-27 1992-03-05 Akzo N.V. Human zona pellucida protein zp3
JPH0614784A (en) * 1991-11-29 1994-01-25 Tonen Corp Dna coding feline ovum clear zone fzp-3, its expressing peptide, and contraceptive vaccine containing the pfptide
JPH05176771A (en) * 1991-11-29 1993-07-20 Tonen Corp Dna cording pig egg clear zone pzp-3
JPH05336974A (en) * 1991-12-26 1993-12-21 Tonen Corp Dna capable of coding canine egg zona pellucida czp-3, czp-3-related peptide coded by the same dna and contraceptive vaccine containing the same peptide
JPH06179698A (en) * 1992-12-15 1994-06-28 Tonen Corp Peptide related to clear zone pzp-3 of pig egg
JPH06217777A (en) * 1993-01-29 1994-08-09 Tonen Corp Dna sequence-coding cat egg transparent zone fzp2

Also Published As

Publication number Publication date
CN1158623A (en) 1997-09-03
FI970744A0 (en) 1997-02-21
AU3471395A (en) 1996-03-14
EP0777688A1 (en) 1997-06-11
CA2198265A1 (en) 1996-02-29
WO1996006113A1 (en) 1996-02-29
HUT77262A (en) 1998-03-02
BR9508748A (en) 1997-08-12
MX9701304A (en) 1998-05-31
FI970744A (en) 1997-02-21
JPH10505340A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
US6641813B1 (en) Methods and reagents for diagnosis of autoantibodies
CA2251464A1 (en) Non-dendritic backbone peptide carrier
KR910016343A (en) Serum Reactive Epitopes of Human Papillomavirus (HPV) 16 Protein
DE3855479D1 (en) HIV PEPTIDES, ARTIFICIAL HIV ANTIGENS AND IMMUNE TESTS
BR9810907A (en) Monoclonal and polyclonal antibodies, peptide capable of generating an antibody, immunogenic agent, nucleotide sequence, pharmaceutical composition, use of at least one antibody, diagnostic kit, and process for preparing an immunogenic agent
JP2008515388A5 (en)
CA2391356A1 (en) Peptides designed for the diagnosis and treatment of rheumatoid arthritis
UY24130A1 (en) PEPTIDO P277 ANALOGS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM FOR THE TREATMENT OR DIAGNOSIS OF DIABETES.
JP2005170951A (en) ANTIBODY TO beta-AMYLOID OR DERIVATIVE THEREOF, AND APPLICATION THEREWITH
Marchalonis et al. Natural human antibodies to synthetic peptide autoantigens: correlations with age and autoimmune disease
KR970705578A (en) NEW IMMUNOCONTRACEPTIVE PEPTIDES (NEW IMMUNOCONTRACEPTIVE PEPTIDES)
CA2117904C (en) Methods and reagents for diagnosis of autoantibodies
Fahrenkrug et al. Production and evaluation of antibodies for radioimmunoassay of secretin
Prohászka et al. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins
JO1671B1 (en) Methods for diagnosis of tuberculosis
WO1997018475A1 (en) Compounds and methods for the detection and prevention of t. cruzi infection
KR930703444A (en) Fish progesterone-releasing hormone homologue
Ekramoddoullah et al. Partial characterization of an antigenic site of high molecular weight basic antigen, a ryegrass pollen allergen, using a monoclonal antibody
EP0595638B1 (en) Epitope-related peptides of human parvovirus
AU636145B2 (en) New human parvovirus peptides with disulfide bridge for immunization or diagnosis
WO1992018528A1 (en) Branched peptides in assays for antibodies
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
KR910007962A (en) HIV related peptides
JPH06293798A (en) Epitope-related peptide of human parvovirus b19
WO1991015584A1 (en) Trypanosoma cruzi recombinant antigens and synthetic peptides for utilization in the immunological diagnosis of chagas disease

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid